Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to eva…
| Periodo | 2026-11 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.10 | $-0.07 | $-0.12 |
| Estimado | $-0.08 | $-0.09 | $-0.11 | $-0.10 |
| Sorpresa | — | -11.1% | +36.4% | -20.0% |
| Métrica | CRDL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -189.2% | -39.2% | -150.0% |
| ROA | -143.2% | -30.9% | -112.2% |
| Current Ratio | 4.16 | 2.73 | +1.43 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -143.2% | — |
| ✗Flujo de caja operativo positivo | −CA$24M | −CA$25M |
| ✗Rentabilidad sobre activos al alza | -143.2% | -115.1% |
| ✓Caja operativa/activos supera al ROA | -101.0% | ROA -143.2% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 4.16 | 4.52 |
| ✗Sin aumentar el nº de acciones | 87M | 72M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -191.0% |
Cardiol Therapeutics Inc. cotiza a 1.10 USD y tiene una capitalización bursátil de $134M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud